Objective: This observational, clinical study was designed to assess the role of sirtuin 1 (SIRT1), sirtuin 6 (SIRT6), and resveratrol in in vitro fertilization (IVF). Methods: Paired serum and follicular fluid (FF) samples were obtained from 30 consecutive patients (age: 36.43 AE 4.17 years, body mass index: 22.90 AE 2.05 kg/m 2 , duration of infertility: 5.10 AE 2.80 years) who received IVF treatment. SIRT1, SIRT6, and resveratrol levels were measured by enzyme-linked immunosorbent assay. Results: Ovarian hyperstimulation resulted in significantly higher serum SIRT1 levels in pregnant women (8 patients) compared with non-pregnant women (22 patients). SIRT6 levels remained unchanged after ovarian hyperstimulation, but were significantly lower in pregnant women compared with non-pregnant women before and after hyperstimulation. Both SIRTs were detected in FF, but they appeared to be independent of their serum levels. After correction for confounders, FF SIRT6 levels were positively related to mature oocytes (F ¼ 6.609), whereas serum SIRT1 and SIRT6 levels were related to clinical pregnancy (F ¼ 10.008, F ¼ 5.268, respectively). Conclusions: Our study shows that SIRT1 and SIRT6, but not resveratrol, are involved in human reproduction and they may have a role in oocyte maturation and clinical pregnancy in IVF.
Introduction
Sirtuins (SIRTs) are a highly conserved protein family of NAD-dependent histone deacetylases that confer protection against ageing and age-related disorders. In mammals, seven members of the SIRT family have been identified (SIRT1-SIRT7) with different subcellular localizations, tissue specificity, activity, and functions. [1] [2] [3] SIRT1, SIRT6, and SIRT7 are localized in the nucleus, SIRT2 is localized at the cytoplasm, and SIRT3, SIRT4, and SIRT5 are expressed in the mitochondria. 4, 5 Generally, SIRTs regulate cellular metabolism, the redox state, stress signalling and the cell cycle, cell survival, and genome stability. [6] [7] [8] A large body of evidence has shown that SIRTs are involved in regulating female reproductive function. 9 With advancing female age, there is a gradual decline in the size of the ovarian follicle pool, oocyte yield, and oocyte quality. This process is termed ovarian ageing. As a result, IVF outcomes deteriorate from 42.6% to 3.6% of live births when maternal age progresses from < 35 years to > 42 years. 10 Studies that applied mouse models of ovarian ageing have clearly shown that SIRT1, SIRT3, and SIRT6 are closely related to ovarian reserve and can be regarded as markers of ovarian ageing. 11 Importantly, expression of SIRTs has been documented in mammalian ovaries, granulosa cells, oocytes, and embryos. [12] [13] [14] [15] [16] Furthermore, the SIRT1-deficient mouse has ovarian dysfunction and compromised oocyte developmental potential. 17 Furthermore, SIRT3 depletion resulted in downregulation of steroidogenic enzymes and caused decreased secretion of progesterone in human granulosa cells. 18 In recent years, important studies have shown that resveratrol (3, 4, 5-trihydroxytrans-stilbene) protects against ageassociated infertility 19 and improves oocyte maturation and subsequent development in various mammals. [19] [20] [21] [22] [23] This polyphenolic compound has anti-ageing, anti-oxidant, anti-inflammatory, and chemopreventive properties. The beneficial effects of resveratrol on female reproduction are thought to be achieved mainly by inducing SIRT1 expression and by promoting telomerase activity with subsequent attenuation of ageing-associated telomere shortening. [20] [21] [22] 24 The present study aimed to investigate involvement of nuclear SIRT1, SIRT6, and resveratrol in the process of IVF in women receiving this treatment. We examined the response pattern of these biologically active compounds with ovarian hyperstimulation and assessed the relationship between serum and follicular fluid (FF) levels of these compounds. Furthermore, we attempted to establish the effects of SIRT1, SIRT6, and resveratrol individually or in combination on reproductive performance as estimated by the number of mature oocytes and embryos, chemical and clinical pregnancy, and live-born infants.
Methods
Obstetrics and Gynaecology, University of Pe´cs, Hungary. During this time, we initiated 30 randomly chosen IVF cycles and performed transvaginal ultrasound-guided aspiration of FF.
The patients were consecutively selected. No patients suffered from any metabolic or vascular diseases, such as obesity, diabetes mellitus, metabolic syndrome, fatty liver diseases, or atherosclerosis, during the study period. The patients had the following main infertility diagnoses: male factors (13, 43.33%), damaged or blocked fallopian tubes (5, 16.67%), severe endometriosis (5, 16.67%), other female factors (6, 20.00%), and unexplained infertility (1, 3.33%).
We performed superovulation treatment after completing some basic examinations. These examinations included a cervical smear, serum hormone measurements (follicle-stimulating hormone [FSH] , luteinizing hormone [LH] , prolactin, oestradiol, progesterone, testosterone, thyroidstimulating hormone) on the 3rd and 21st days of the unstimulated cycles, human immune deficiency virus and hepatitis-B surface antigen screening, hysteroscopy or hysterosalpingo-contrast sonography, and an andrological examination. Two independent gynaecologists approved participation of the patients in the IVF procedure.
Controlled ovarian hyperstimulation
The gonadotropin-releasing hormone agonist triptorelin (Gonapeptyl; Ferring, Kiel, Germany) was used in a long or short protocol. Stimulation was performed with individual dosages of recombinant FSH (Gonal-F; Serono, Aubonne, Switzerland), which varied from 150 to 250 IU per day depending on follicular maturation. The starting dose was adapted according to the body mass index (BMI) and age. For patients with a previously known low response, recombinant FSH was increased to a maximum dose of 300 IU daily. 
Collection of blood serum and FF
Blood samples were obtained from the patients before the stimulated cycle on the 21st day of their menstrual cycle and in the morning of follicular puncture before sedation. Oocyte and FF collection was performed using the Sonoace 6000C two-dimensional real-time ultrasound scanner equipped with a 4-to 8-MHz endovaginal transducer in G-MOPS TM medium (Vitrolife, G€ oteborg, Sweden). The fluid was centrifuged for 10 minutes at 252 Â g and the supernatants were frozen and stored at À80 C for future analysis.
Fertilization procedures
The fertilization process was carried out with intracytoplasmic sperm injection (ICSI) depending on the andrological status (sperm count <15 M/mL), maternal age (>35 years), and the number of previous IVF cycles the patients had undergone previously (>2). The oocytes that were selected for ICSI and denuded with hyaluronidase were checked for maturity. Only metaphase II oocytes that showed the presence of the first polar body were selected for fertilization. ICSI was performed 3 to 6 hours later in G-MOPS TM medium (Vitrolife). The other oocytes were fertilized with the conventional IVF method in a bicarbonatebuffered medium (G-IVF TM , Vitrolife). Fertilization was checked in G-Iv5 TM medium (Vitrolife) 24 hours later.
Embryo transfer was carried out 3 to 5 days after follicular puncture. G-21Mv5 medium (Vitrolife) was used from day 3 to the blastocyst stage. Only the best quality embryos were transferred (according to the consensus embryo scoring system of the European Society of Human Reproduction and Embryology). Upon the patient's request, one, two, or three embryos were transferred. The remaining embryos were frozen in compliance with Hungarian law. A total of 300 mg of progesterone was prescribed to support the luteal phase (Utrogestan; Lab. Besins International S. A., Paris, France). Evaluation of treatment was performed by a transvaginal ultrasound examination to detect a gestational sac 21 days after embryo transfer.
Laboratory measurements
Laboratory measurements were performed by using commercially available enzymelinked immunosorbent assay (ELISA) kits. SIRT1, SIRT6, and resveratrol kits were produced by Cloud-Clone Corporation (Houston, TX, USA) The intra-and interassay coefficients of variation were <10% and <12%, respectively, for each kit. The detection limits for SIRT1, SIRT6, and resveratrol levels were 0.27, 0.115, and 246.9 ng/mL, respectively.
Ethics approval and consent to participate
The study was reviewed and approved by the Human Reproduction Committee of the Hungarian Medical Research Council (5273-2/2012/EHR). Informed consent was signed by the patients who participated in the study. The investigation conformed to the principles outlined in the Declaration of Helsinki.
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA).
Normality of data distribution was tested by the Kolmogorov-Smirnov test. Depending on distribution of data, the Student's paired or independent t-test was used to compare continuous variables. The association between two continuous variables was tested by using Spearman's or Pearson's correlation coefficients. Analysis of covariance was used to examine the effect of SIRT1, SIRT6, and resveratrol levels on outcome measures in patients with IVF. The Bonferroni test was used for multiple comparisons. Data are expressed as mean AE standard deviation. A value of p < 0.05 was considered statistically significant.
Results
The clinical parameters of the patients are shown in Table 1 . A total of 30 patients were included in the study. In response to ovarian hyperstimulation, serum SIRT1 levels tended to increase (p ¼ 0.378) and SIRT6 levels remained unchanged, but resveratrol levels were significantly increased (p ¼ 0.009) compared with those before ovarian hyperstimulation. FF levels of SIRT1 and resveratrol were markedly lower than those in serum (both p < 0.001; Table 2 ), while FF SIRT6 levels were similar to serum levels.
Patients who underwent successful IVF treatment and progressed to clinical pregnancy and delivery at term (8 patients, pregnant group) were compared with those who failed to become pregnant (22 patients, non-pregnant group) ( Table 2) . A similar response pattern was observed after Numbers 1, 2, and 3 represent serum samples before (1) and after ovarian hyperstimulation (2), and follicular fluid samples (3). *p < 0.05, compared with the non-pregnant group; significant intra-group difference between values before and after ovarian hyperstimulation: p< 0.05,
hyperstimulation in serum and FF levels of SIRT1 and resveratrol, but no difference was detected in SIRT6 levels in either group. Pregnant patients had significantly higher post-hyperstimulation SIRT1 levels compared with those in non-pregnant patients (p ¼ 0.039). In pregnant patients, pre-hyperstimulation serum and FF SIRT1 levels appeared to be higher than those in non-pregnant patients, but this did not reach significance. In contrast to SIRT1, serum SIRT6 levels were significantly lower in pregnant women (before and after hyperstimulation, p ¼ 0.002 and p ¼ 0.049, respectively) compared with non-pregnant women. FF resveratrol levels were also significantly lower in pregnant women compared with non-pregnant women (p ¼ 0.014), but serum resveratrol levels were similar in the two groups.
To examine the possible contribution of circulating SIRTs and resveratrol to their respective FF levels, we examined the relationship between the corresponding parameters that were measured simultaneously in serum and FF. A significant positive correlation was found between posthyperstimulation serum and FF resveratrol levels (r ¼ 0.555, p ¼ 0.002). However, we failed to demonstrate such an association for SIRT1 and for SIRT6 levels. This finding suggested that local ovarian production of these SIRTs predominates over their serum-derived fraction.
Maternal age negatively affected serum SIRT1 and resveratrol levels (SIRT1 after hyperstimulation: r ¼ À0.427, p ¼ 0.029; resveratrol before hyperstimulation: r ¼ 0.400, p ¼ 0.032, Table 3 ). A further negative association was found between FSH dosage and serum SIRT1 levels (r ¼ À0.379 and À0.488 before and after hyperstimulation, both p < 0.05). However, serum SIRT1 levels were We found that serum SIRT1 levels (F ¼ 10.008, p ¼ 0.005) and serum SIRT6 levels (F ¼ 5.268, p ¼ 0.031) had a significant effect on the occurrence of clinical pregnancy. Moreover, FF SIRT6 levels were significantly higher in patients with a mature oocyte number of !10 than in those of 9 (0.515 AE 0.193 ng/mL versus 0.288 AE 0.176 ng/mL; F ¼ 6.609, p ¼ 0.016).
Discussion
The present study showed that in women who underwent IVF, ovarian hyperstimulation resulted in an elevation in serum SIRT1 levels in patients who progressed to clinical pregnancy. In contrast, SIRT6 levels remained unchanged after ovarian hyperstimulation and they were markedly reduced in pregnant women compared with non-pregnant women. Both SIRTs were detected in FF, but they appeared to be independent of their serum levels, which suggested that FF SIRT1 and SIRT6 levels were mostly derived from local ovarian production. With measurement of resveratrol in serum and FF samples, we could not provide evidence for resveratrol stimulation of SIRT1 and SIRT6. Univariate linear regression showed that the outcome measures of IVF were independent of SIRTs. However, when corrections were made for confounders, serum SIRT1 and SIRT6 levels were positively related to clinical pregnancy and FF SIRT6 levels were related to the number of mature oocytes.
With regard to function in female reproduction, nuclear SIRT1 and SIRT6 and mitochondrial SIRT3 are the most extensively studied SIRTs. SIRT1 protects cells against oxidative stress, regulates glucose/ lipid metabolism, promotes DNA stability, and extends the lifespan. 25, 26 SIRT1 regulates the metabolic response to caloric restriction, which is the main factor in slowing down ageing and in reducing agerelated disorders. 27 SIRT1 may mediate diverse cellular responses because its substrates can be histone-modifying enzymes, transcription factors, regulators of cell cycle progression/survival under stress, cell signalling components, DNA repair modulators, and regulators of metabolism.
28
SIRT1 has also been identified as a positive regulator of telomere length because it attenuates telomere shortening associated with ageing. 29 Importantly, posttranslational modification of SIRT1 by different kinases may exert either stimulatory or inhibitory effects on its activity. 30 Involvement of SIRT1 in female reproductive function has also been established. In addition to various mammalian species [11] [12] [13] [14] [15] SIRT1 mRNA abundance has been detected in human granulosa cells, and its regulatory role in progesterone secretion, aromatase expression, and oestrogen synthesis has been demonstrated. 28, 31 Most recently, Zhao et al. 32 provided evidence that all seven members of the SIRT family were present in human germinal vesicles and in mature oocytes in vivo or in vitro. However, the relative abundance of SIRTs in in vivo mature oocytes exceeded that of mature oocytes in vitro. Our study also provided evidence for local ovarian production of SIRT1 and it showed an association with clinical pregnancy. Importantly, an association has been reported between telomere length in the cumulus-oocyte complex and oocyte/ embryo quality in women undergoing IVF. 33 There is also convincing evidence that SIRT1 and SA1/SA2 cohesion proteins modulate telomere homeostasis in cumulus cells.
34 SIRT1 expression correlates with cohesion proteins, telomere length, response patterns to ovarian stimulation (oocyte number >6 versus <4), maternal age (>38 versus <34 years), and BMI (>25 versus <25 kg/m 2 ).
34
SIRT6 has multiple enzymatic activities and regulates DNS repair and telomere maintenance when challenged by oxidative stress. Furthermore, SIRT6 functions as a nutrient sensor and controls glucose and lipid metabolism. 35 In mouse oocytes, SIRT6 depletion resulted in inadequate histone deacetylation, chromosome missegregation, and aneuploidy with subsequent defects in embryonic development. 36, 37 In humans, SIRT6 was also found to be expressed in germinal vesicles, and SIRT6 was upregulated during maturation in in vivo and in vitro mature oocytes. 32 The present study showed SIRT6 levels in the maternal circulation and FF, which suggested a role in oocyte maturation and in early embryonic development. Unexpectedly, serum levels of SIRT6 were markedly reduced in women who progressed to clinical pregnancy compared with those of non-pregnant women. However, FF SIRT6 levels were positively related to the mature oocyte number and serum SIRT6 levels had a positive effect on successful pregnancy when adjustments were made for relevant clinical and biochemical confounders.
On the basis of compelling evidence on the fertility-sparing effects of resveratrol in mammalian females, we anticipated a positive association of serum and/or FF resveratrol levels with SIRTs and IVF outcome measures. 38 The protective effects of resveratrol are due to induction of progesterone secretion and to its anti-oxidant properties that are closely related to an increase in SIRT1 expression. 19, 20 Our failure to reveal such an association might be explained by the relatively low concentration of resveratrol present to exert its dose-dependent stimulation of expression/ action of SIRT1.
Conclusions
Although our study provides some circumstantial evidence for involvement of SIRTs in control of folliculogenesis, oocyte maturation, and developmental potential of early embryos, definitive conclusions cannot be drawn. We measured immunoreactive SIRT1 and SIRT6 protein levels, which are not reliable measures of their function. SIRT proteins may dissociate from their mRNA expression because they may undergo post-translational modifications. Epigenetic damage by phosphorylation or by small interfering RNA may alter conformation of SIRT protein, binding to their substrates, catalytic activity, and immunoreaction. 30, 36 Because these modifications cannot be detected by ELISA, further studies need to be conducted to determine the molecular mechanism of SIRT function in patients receiving IVF. scientific workshops of medical, health sciences and pharmaceutical educations") and GINOP-2.3.2-15-2016-00021 ("The use of chiptechnology in increasing the effectiveness of human in vitro fertilization"). The funding sources did not have any role in the study design, in collection, analysis and interpretation of data, or in writing and submitting this manuscript.
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